Extended Release of ISMN
The technology suggests a pharmaceutical composition useful for extended release of isosorbide mononitrate to an environment of use. More specifically, the present invention relates to a novel pharmaceutical composition for extended release of isosorbide mononitrate, which operates on the principles of diffusion, osmotic pressure, or a combination of both. The use of extended release formulation will provide a more uniform plasma concentration of ISMN for a definite period of time and will tend to avoid the peak and trough effects associated with immediate release formulations. The frequency of daily administration will be reduced and a uniform plasma concentration for a definite period of time will avoid any development of tolerance, resulting in enhanced patient compliance. All the above side effects of ISMN and the fact that the half-life of the drug is around 4 to 5 hours, the advantages of a pharmaceutical composition for extended release of ISMN, appear evident.
Area of Application: ISMN,isosorbide mononitrate
Advantages: Extended release of ISMN Reduces frequency of daily administration. Uniform plasma concentration of ISMN for a definite period of time. Enhanced patient compliance.
Environmental aspects: Not Applicable
Development Status: Laboratory Model
Legal Protection: Patent
Transfer Terms: Technology Licensing
Target Countries: India
Estimated cost (US$):
Upload any relevant document:
Contact Person: SkyQuest Technology Consulting Pvt. Ltd.
Address: 501, Krishna Complex, Opp. Devashish School, Bodakdev
Zip/Pin Code: 380054